Haas Joel T, Francque Sven, Staels Bart
European Genomic Institute for Diabetes (EGID), FR 3508, F-59000 Lille, France; email:
Université de Lille, F-59000 Lille, France.
Annu Rev Physiol. 2016;78:181-205. doi: 10.1146/annurev-physiol-021115-105331. Epub 2015 Nov 30.
Nonalcoholic fatty liver disease (NAFLD) encompasses a spectrum of liver disorders characterized by abnormal hepatic fat accumulation, inflammation, and hepatocyte dysfunction. Importantly, it is also closely linked to obesity and the metabolic syndrome. NAFLD predisposes susceptible individuals to cirrhosis, hepatocellular carcinoma, and cardiovascular disease. Although the precise signals remain poorly understood, NAFLD pathogenesis likely involves actions of the different hepatic cell types and multiple extrahepatic signals. The complexity of this disease has been a major impediment to the development of appropriate metrics of its progression and effective therapies. Recent clinical data place increasing importance on identifying fibrosis, as it is a strong indicator of hepatic disease-related mortality. Preclinical modeling of the fibrotic process remains challenging, particularly in the contexts of obesity and the metabolic syndrome. Future studies are needed to define the molecular pathways determining the natural progression of NAFLD, including key determinants of fibrosis and disease-related outcomes. This review covers the evolving concepts of NAFLD from both human and animal studies. We discuss recent clinical and diagnostic methods assessing NAFLD diagnosis, progression, and outcomes; compare the features of genetic and dietary animal models of NAFLD; and highlight pharmacological approaches for disease treatment.
非酒精性脂肪性肝病(NAFLD)涵盖了一系列肝脏疾病,其特征为肝脏脂肪异常堆积、炎症以及肝细胞功能障碍。重要的是,它还与肥胖和代谢综合征密切相关。NAFLD使易感个体易患肝硬化、肝细胞癌和心血管疾病。尽管确切的信号仍知之甚少,但NAFLD的发病机制可能涉及不同肝细胞类型的作用以及多种肝外信号。这种疾病的复杂性一直是制定其进展的适当指标和有效治疗方法的主要障碍。最近的临床数据越来越重视纤维化的识别,因为它是肝病相关死亡率的有力指标。纤维化过程的临床前建模仍然具有挑战性,尤其是在肥胖和代谢综合征的背景下。需要未来的研究来确定决定NAFLD自然进展的分子途径,包括纤维化和疾病相关结局的关键决定因素。这篇综述涵盖了来自人类和动物研究的NAFLD不断演变的概念。我们讨论了评估NAFLD诊断、进展和结局的最新临床和诊断方法;比较了NAFLD遗传和饮食动物模型的特征;并强调了疾病治疗的药理学方法。